Newsroom | 4682 results

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced that final results from the Phase 3 METIS trial of Tumor Treating Fields (TTFields) therapy for brain metastases from non-small cell lung cancer (NSCLC) will be presented today at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting taking place September 27 – October 1 in San Francisco and simultaneously published in the International Journal of Radiation Oncology Biology and Physics (Red Journal). “Lung c...

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies announces pricing of $4.8 million public offering....

NEW YORK--(BUSINESS WIRE)--Radformation Inc, a leading provider of intelligent automation solutions for radiation oncology, today announced a new collaboration with Icon Group, a leading global integrated cancer care provider, to implement Radformation’s Offline Adaptive Assessment solution across its clinical network. This initiative represents an important step in the ongoing partnership and bringing practical, scalable adaptive radiotherapy workflows to patients and clinics globally. Daily a...

SAN FRANCISCO--(BUSINESS WIRE)--Varian, a Siemens Healthineers company, announced major advancements for its Halcyon treatment platform at the ASTRO 2025 Annual Meeting, including new, enhanced patient positioning, improved real-time motion management, and embedded high-quality cone beam CT imaging. These innovations represent the most advanced evolution of Halcyon to date, aimed at improving treatment precision, efficiency, and the overall patient experience. Halcyon was built to maximize effi...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the prospective, randomized integral biomarker BALANCE trial (NCT03371719) finds that the PAM50 molecular signature predicts which patients with recurrent prostate cancer benefit from hormone therapy with apalutamide in addition to salvage radiation therapy. The prostate PAM50 biomarker is currently available for Research Use Only on the Decipher GRID...

LOS ANGELES--(BUSINESS WIRE)--MiraDx, a molecular diagnostics company advancing germline-based personalization of cancer treatment, announced today a study from UCLA that will be presented at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place September 27 to October 1, 2025, in San Francisco, Calif. The study, conducted by UCLA and other leading academic institutions, used MiraDx’s PROSTOX ultra test to identify prostate cancer patients at higher risk of late...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--New Data on Hologic’s AI-Powered Mammography Technology to Be Presented at EUSOBI...

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies shares 3 new case studies in which CyPath Lung detected Stage 1A lung cancer or prevented unnecessary invasive procedures....

ATLANTA--(BUSINESS WIRE)--Mirion Technologies, Inc. (“Mirion”) (NYSE: MIR), today announced the pricing of an underwritten public offering of 17,309,846 shares of Mirion’s Class A common stock at a public offering price of $21.35 per share (the “common stock offering”). The size of the common stock offering was increased from the previously announced $350.0 million of shares of Class A common stock. In addition, Mirion granted the underwriters an option to purchase up to an additional 2,596,476...

DUBLIN--(BUSINESS WIRE)--The "World Market for AI in Medical Imaging 2025-2032" report has been added to ResearchAndMarkets.com's offering. Radiology faces a triple squeeze: rising scan volumes, stagnant radiologist head-count, and fast-evolving reimbursement that now rewards computer-assisted detection, triage, and quantification. AI is no longer experimental; it is operational. Capital allocation is shifting, yet market signals remain noisy - valuations, attach-rate assumptions, and regulator...